Tibotec’s long-awaited, well-studied protease inhibitor (PI) TMC114 will be in expanded access this fall (www.tibotec.com will have details soon). The PI boasts a resistance pattern all its own, holding hope for those who’ve run out of PIs. Boosted with  Norvir and paired with a med to which you’re not resistant—like entry inhibitor Fuzeon—it promises to lower rising viral loads. Expect FDA approval of 114 in ’06.